AMYLOID PETMEASUREMENTS AND EVALUATE AMYLOID-MODIFYING TREATMENTS USING A CEREBRALWHITE MATTER REFERENCE REGION-OF-INTEREST Kewei Chen, Auttawut Roontiva, Pradeep Thiyyagura, Wendy Lee, Xiaofen Liu, Napatkamon Ayutyanont, Hillary Protas, Susan Landau, Ji Luo, Robert Bauer, III,, Cole Reschke, Dan Bandy, Robert Koeppe, Adam S. Fleisher, Richard J. Caselli, William Jagust, Michael Walter Weiner, Eric M. Reiman, Banner Alzheimer’s Institute, Arizona State University, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; 2 Banner Alzheimer’s Institute, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; Banner Alzheimer’s Institute, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; 4 Banner Alzheimer’s Institute, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; 5 University of California, Berkeley, Berkeley, California, United States; Banner Alzheimer’s Institute, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; Banner Alzheimers Institute, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; University of Michigan, Ann Arbor, Michigan, United States; Banner Alzheimer’s Institute, Eli Lilly & Co, Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States; 10 Mayo Clinic, Arizona Alzheimer’s Consortium, Scottsdale, Arizona, United States; 11 Center for Imaging of Neurodegenerative Diseases, VAMedical Center and UCSF, San Francisco, California, United States; Banner Alzheimer’s Institute, University of Arizona, Translational Genomics Research Institute, Phoenix, Arizona, United States. Contact e-mail: kewei.chen@bannerhealth.com